The Possible Role of Interleukin (IL)-12 and Interferon-γ-Inducing Factor/IL-18 in Protection against ExperimentalMycobacterium lepraeInfection in Mice
{"title":"The Possible Role of Interleukin (IL)-12 and Interferon-γ-Inducing Factor/IL-18 in Protection against ExperimentalMycobacterium lepraeInfection in Mice","authors":"Kazuo Kobayashi , Masanori Kai , Masa-ichi Gidoh , Noboru Nakata , Masumi Endoh , Ram Pyare Singh , Tsuyoshi Kasama , Hajime Saito","doi":"10.1006/clin.1998.4533","DOIUrl":null,"url":null,"abstract":"<div><p>Cell-mediated immunity participates in host defense against mycobacterial infection. Both interleukin 12 (IL-12) and interferon-γ-inducing factor (IGIF/IL-18), produced mainly by macrophages, play a critical role in expression of cell-mediated immunity. To investigate the role of IL-12 and IGIF/IL-18<em>in vivo,</em>we examined cytokine profile, bacterial growth, and the potential benefit of cytokine therapy in susceptible and resistant mice infected with<em>Mycobacterium leprae.</em>The early expression of IL-12 p40 and IGIF/IL-18 at the site of inoculation was found in resistant mice 3–72 h after the infection, but not in susceptible mice. Both strains of mice did not show expression of IFN-γ and IL-4. IL-12 administration resulted in a significant reduction of bacterial counts in mice with established<em>M. leprae</em>infection. The results imply that susceptible mice exhibit decreased expression of type 1 helper T (Th1) response without reciprocal increased Th2 response and show responsiveness to exogenous IL-12. IL-12 therapy may be a possible rationale for treatment of<em>M. leprae</em>infection.</p></div>","PeriodicalId":10683,"journal":{"name":"Clinical immunology and immunopathology","volume":"88 3","pages":"Pages 226-231"},"PeriodicalIF":0.0000,"publicationDate":"1998-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1006/clin.1998.4533","citationCount":"80","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical immunology and immunopathology","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0090122998945330","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 80
Abstract
Cell-mediated immunity participates in host defense against mycobacterial infection. Both interleukin 12 (IL-12) and interferon-γ-inducing factor (IGIF/IL-18), produced mainly by macrophages, play a critical role in expression of cell-mediated immunity. To investigate the role of IL-12 and IGIF/IL-18in vivo,we examined cytokine profile, bacterial growth, and the potential benefit of cytokine therapy in susceptible and resistant mice infected withMycobacterium leprae.The early expression of IL-12 p40 and IGIF/IL-18 at the site of inoculation was found in resistant mice 3–72 h after the infection, but not in susceptible mice. Both strains of mice did not show expression of IFN-γ and IL-4. IL-12 administration resulted in a significant reduction of bacterial counts in mice with establishedM. lepraeinfection. The results imply that susceptible mice exhibit decreased expression of type 1 helper T (Th1) response without reciprocal increased Th2 response and show responsiveness to exogenous IL-12. IL-12 therapy may be a possible rationale for treatment ofM. lepraeinfection.